Abstract:The main aim of pharmacotherapeutics is the attainment of an effective drug concentration at the intended site of action for a sufficient period of time to elicit the response. A major problem being faced in ocular therapeutics is the attainment of an optimal concentration at the site of action. Poor bioavailability of drugs from ocular dosage forms is mainly due to the tear production, non-productive absorption, transient residence time, and impermeability of corneal epithelium. This article reviews: (1) the barriers that decrease the bioavailability of an ophthalmic drug; (2) the objectives to be considered in producing optimal formulations; and (3) the approaches being used to improve the corneal penetration of a drug molecule and delay its elimination from the eye. The focus of this review is on the recent developments in topical ocular drug delivery systems, the rationale for their use, their drug release mechanism, and the characteristic advantages and limitations of each system. In addition, the review attempts to give various analytical procedures including the animal models and other models required for bioavailability and pharmacokinetic studies. The latter can aid in the design and predictive evaluation of newer delivery systems. The dosage forms are divided into the ones which affect the precorneal parameters, and those that provide a controlled and continuous delivery to the pre- and intraocular tissues. The systems discussed include: (a) the commonly used dosage forms such as gels, viscosity imparting agents, ointments, and aqueous suspensions; (b) the newer concept of penetration enhancers, phase transition systems, use of cyclodextrins to increase solubility of various drugs, vesicular systems, and chemical delivery systems such as the prodrugs; (c) the developed and under-development controlled/continuous drug delivery systems including ocular inserts, collagen shields, ocular films, disposable contact lenses, and other new ophthalmic drug delivery systems; and (d) the newer trends directed towards a combination of drug delivery technologies for improving the therapeutic response of a non-efficacious drug. The fruitful resolution of the above-mentioned technological suggestions can result in a superior dosage form for both topical and intraocular ophthalmic application.

Design and Development of Ophthalmic Liposomes from the QbD Perspective

Design and development of topical liposomal formulations in a regulatory perspective

Quality by design steered approach for co-encapsulation of timolol maleate and dorzolamide hydrochloride in injectable liposomes

Development of liposomes using formulation by design: Basics to recent advances

Review of Approaches for Increasing Ophthalmic Bioavailability for Eye Drop Formulations

A novel liposomal formulation for ocular delivery of caspofungin: an experimental study by quality by design-based approach

Ocular Preparations: The Formulation Approach

Lipid-based eye drop formulations for the management of evaporative dry eyes

Design of liposomal nanocarriers with a potential for combined dexamethasone and bevacizumab delivery to the eye

Ophthalmic and Otic Drug Administration: Novel Approaches and Challenges

Comparative study of cyclosporine A liposomes and emulsions for ophthalmic drug delivery: Process optimization through response surface methodology (RSM) and biocompatibility evaluation

Lipid-Based Nanocarriers for Ophthalmic Administration: Towards Experimental Design Implementation

Quality by design (QbD) in the formulation and optimization of liquid crystalline nanoparticles (LCNPs): A risk based industrial approach

Lipid Nanoparticles as a Promising Drug Delivery Carrier for Topical Ocular Therapy—An Overview on Recent Advances

A Review on Ocular Drug Delivery System

Novel Eye Drop Delivery Systems: Advance on Formulation Design Strategies Targeting Anterior and Posterior Segments of the Eye

Liposomes as vehicles for topical ophthalmic drug delivery and ocular surface protection

Quality by Design Approach in Liposomal Formulations: Robust Product Development

Liposome‐Based Permeable Eyedrops for Effective Posterior Segment Drug Delivery

CATIONIC NANOSTRUCTURED LIPID CARRIERS: OPTIMIZATION OF ZETA POTENTIAL AND EVALUATION

Development and evaluation of ocular drug delivery system